Trials / Withdrawn
WithdrawnNCT03749083
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
In this research study, the investigators are looking to see if the circulating tumor DNA (genetic material), also known as ctDNA, in the blood will help them predict whether the participant's cancer will come back.
Detailed description
In this research study, the investigator are performing blood draws to see if the presence or absence of circulating tumor DNA (ctDNA), the genetic material in the participant's cancer's cells, will help the investigators predict whether the participant's cancer will come back or not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | The Functional Assessment of Cancer Therapy- Colorectal | The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses. |
Timeline
- Start date
- 2019-12-31
- Primary completion
- 2021-10-31
- Completion
- 2024-10-31
- First posted
- 2018-11-21
- Last updated
- 2019-07-08
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03749083. Inclusion in this directory is not an endorsement.